|View printer-friendly version|
|August 27, 2007 1:54 p.m.|
|Teva Announces Approval Of Generic Accupril® Tablets|
Jerusalem, Israel, August 27, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that, following the expiration of pediatric exclusivity for U.S. Patent No. 4,743,450, the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Pfizer's hypertension treatment Accupril® (Quinapril Hydrochloride Tablets, 5 mg, 10 mg, 20 mg and 40 mg. Shipment of this product will commence shortly. Total annual sales of Quinapril HCl Tablets in the U.S., including brand and generic sales, were approximately $150 million for the twelve months ended June 30, 2007, based on IMS sales data.